VersaMatrix A/S Launches Versaffin™ for Affinity Resin-Mediated Bioseparation

VersaMatrix A/S has announced the global launch of Versaffin™, the Company’s proprietary bead-encoding technology to produce Customized Affinity Ligands – small molecules that can selectively bind and release desired proteins and other biomolecules. 

Ligands derived using Versaffin™ provide performance in affinity chromatography for the purification of biopharmaceutical drugs.

VersaMatrix has developed Versaffin™ to solve this problem by ensuring the fast development of Customized Affinity Ligands.

The technology provides information on relative binding and elution of target proteins to all members of large libraries of ligands. 

Ib Johannsen, VersaMatrix’ CEO commented, "Versaffin™ ensures that affinity ligands can be developed in a matter of weeks instead of months."

"This time reduction translates into cost savings for cash strapped biopharmaceutical companies moving into protein production."

"We are confident that our technology will help the industry boost its profits from biopharmaceuticals!"